x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

MedTech Global Insights

What"s next in the future of health? Welcome to MedTech Global Insights, the podcast dedicated to uncovering the most disruptive technologies and brilliant minds in the medical field. Whether you"re an industry professional, investor, or simply curious, subscribe for your dose of cutting-edge information and expert commentary.

science life sciences

All Episodes

02:00

USA's FDA QMSR: Pure Global on Hidden Management...

MedTech Global Insights ·

2026/03/27

This week, MedTech Global Insights dives into the most significant U.S. regulatory shift of 2026: the FDA's new Quality Management System Regulation (QMSR). We uncover why this is far more than a simple alignment with international standards and exposes a new level of corporate liability.The episode reveals how FDA inspectors now have unprecedented access to high-level management review meetings. We explore a real-world case where a company's internal decision to 'monitor' a component risk, once a

en

01:48

Pure Global: USA MedTech Security & Why FDA's...

MedTech Global Insights ·

2026/03/26

The FDA's "honeymoon phase" for medical device cybersecurity is over. In this episode, we dissect the agency's heightened scrutiny on premarket submissions, moving beyond simple documentation to active verification. We explore the new, unwritten rules manufacturers must follow to avoid costly rejections.We look at the case of a company whose 510(k) submission was delayed for months. Despite providing a complete Software Bill of Materials (SBOM), they were rejected because a common open-source

en

02:15

USA 510(k) Cybersecurity: The 'Refuse to Accept' Trap...

MedTech Global Insights ·

2026/03/25

The FDA has drawn a new line in the sand for medical device market access, and non-compliance means immediate rejection. With the full implementation of Section 524B of the FD&C Act, robust cybersecurity documentation is no longer optional for any 510(k) submission of a connected "cyber device." This episode breaks down the critical new requirements that are already impacting market entry timelines.We explore the costly lesson of a European AI startup whose promising 510(k) submission was

en

01:50

U.S. AI Medical Devices: Cracking the New Code | Pure...

MedTech Global Insights ·

2026/03/24

This week on MedTech Global Insights, we dissect the groundbreaking new draft guidance from the U.S. FDA on AI and Machine Learning medical devices. This pivotal announcement introduces new requirements for adaptive algorithms, fundamentally changing the regulatory landscape for software as a medical device (SaMD) manufacturers worldwide. We explore what the new "Predetermined Change Control Plan" means for your technical dossier, validation strategies, and post-market surveillance. We break down

en

02:03

Pure Global: USA Robotic Surgery & FDA's Digital...

MedTech Global Insights ·

2026/03/23

This week, MedTech Global Insights explores a critical challenge for international manufacturers entering the U.S. market. We analyze the recent case of a leading Japanese robotics firm whose 510(k) submission for an innovative surgical system was rejected by the FDA. The cause was not clinical failure, but non-compliance with new digital submission standards and cybersecurity protocols.This episode breaks down the costly administrative and technical hurdles that can blindside even the most

en

02:00

US AI Diagnostics: Pure Global on FDA's Hidden Hurdles

MedTech Global Insights ·

2026/03/22

This week on MedTech Global Insights, we dive into a crucial, under-the-radar development from the U.S. FDA. We explore the recent clearance of an AI-powered triage tool for stroke detection and what this single approval reveals about the future of AI regulation in American healthcare. We move beyond the hype of algorithms and predictive accuracy to uncover the real challenges and expectations the FDA has for MedTech innovators. This episode is essential for anyone developing or seeking approval

en

01:59

Pure Global: EU MedTech's EUDAMED Deadline & Its...

MedTech Global Insights ·

2026/03/21

The clock is ticking on a major regulatory shift in the European Union. With the mandatory use of key EUDAMED modules fast approaching, the era of radical transparency for medical devices is here. This isn't just a compliance update; it's a fundamental change that exposes manufacturers to new levels of public and competitor scrutiny, where every piece of data is visible to the world.This episode of MedTech Global Insights unpacks the hidden risks and strategic challenges of the EUDAMED transition

en

01:47

USA's AI MedTech Shift: Pure Global on the FDA's...

MedTech Global Insights ·

2026/03/20

The U.S. FDA is changing the rules for AI in medical devices, promising faster innovation. This new framework allows for pre-approved algorithm updates, potentially slashing go-to-market timelines. But this speed comes with a cost.This episode of MedTech Global Insights unpacks the FDA's new guidance on Predetermined Change Control Plans (PCCPs). We explore how this shifts the regulatory burden from pre-market review to post-market vigilance and places immense new pressures on manufacturers to

en

01:56

Pure Global: EU IVDR Software's Silent Compliance Crisis

MedTech Global Insights ·

2026/03/19

The European IVDR continues to challenge MedTech manufacturers with inconsistent interpretations and sudden shifts in compliance requirements. This episode dives into a recent and critical development: the "silent reclassification" of certain diagnostic software, which is forcing companies to pull products from the market and re-evaluate their entire regulatory strategy.We explore a case study of a cancer risk-scoring software company that found its product non-compliant overnight due to a new

en

02:07

USA MedTech: Pure Global on the EU Post-Market Data Trap

MedTech Global Insights ·

2026/03/18

This week on MedTech Global Insights, we explore the hidden challenges of using European post-market data for FDA submissions. Following the FDA's recent guidance on Real-World Evidence (RWE), many non-U.S. manufacturers assumed their path to the American market would be easier. We reveal why that is often not the case.We break down the fundamental differences between the EU's requirements for Post-Market Surveillance and the FDA's expectations for RWE. This disconnect can lead to significant

en

01:53

EU's IVDR Surprise: Pure Global on the Legacy Device...

MedTech Global Insights ·

2026/03/17

This week, we dissect the European Commission's surprise March 2026 guidance document that is reshaping the IVDR transition for legacy devices. This last-minute clarification on clinical evidence requirements has invalidated the long-held assumption that a history of safe use is enough, creating an urgent documentation crisis for many established IVD products. We explore how this shift from passive to active data collection is catching even experienced manufacturers off guard. We break down the

en

01:43

China's Neuro-Device Shortcut: Pure Global's...

MedTech Global Insights ·

2026/03/16

China's NMPA just launched a new 'Green Channel' fast-track approval pathway for innovative neurology devices. This policy could slash market entry timelines for MedTech companies, but the requirements are stringent and differ significantly from FDA or EU standards. This episode breaks down what the new rules mean for global manufacturers. We dissect the NMPA's specific criteria for 'innovation,' discuss the potential pitfalls in the application process, and outline the strategic adjustments

en

01:54

Pure Global: UK's MedTech Shortcut & The Regulatory...

MedTech Global Insights ·

2026/03/15

The UK's MHRA is rolling out a new "regulatory reliance" pathway, promising to fast-track medical devices already approved in the US, EU, Canada, and other key markets. This could slash market entry times and costs, representing a major opportunity for MedTech manufacturers looking to expand their global footprint.However, this shortcut introduces new and complex strategic risks. What happens if your original FDA approval is modified or has new conditions attached? This episode explores how this

en

02:06

Pure Global: Germany's IVD Deadline & The SME...

MedTech Global Insights ·

2026/03/14

The European Union's In Vitro Diagnostic Regulation (IVDR) is creating a critical challenge for small and medium-sized MedTech companies. With deadlines looming, a severe shortage of Notified Bodies and an explosion in documentation requirements are putting immense pressure on innovators, forcing some to consider discontinuing established and vital diagnostic tools.This episode dives into the heart of the crisis, using Germany's vibrant SME sector as a case study. We explore the real-world

en

01:37

Pure Global: Minneapolis MedTech's Unseen Pre-Sub...

MedTech Global Insights ·

2026/03/13

This week, MedTech Global Insights dives into the increasingly complex regulatory landscape facing U.S. MedTech startups in early 2026. While funding initiatives aim to boost innovation, the FDA is raising the bar, demanding more rigorous data and strategic foresight than ever before. This episode explores the unseen hurdles that can derail a promising device's journey to market.We break down the shift in FDA expectations, focusing on why a proactive, integrated regulatory strategy is no longer

en

02:08

Pure Global: US MedTech's Hidden Cybersecurity...

MedTech Global Insights ·

2026/03/12

Last week, the FDA's intensified cybersecurity enforcement sent shockwaves through the MedTech industry, leading to a surge in 'Refuse to Accept' notices for new device submissions. This episode of MedTech Global Insights delves into the critical new requirements that are halting market access and catching even seasoned companies off guard.We uncover why traditional regulatory strategies are no longer sufficient and how the FDA's mandate for a total product lifecycle security plan is fundamentally

en

01:38

Pure Global: EU's New AI Rules & The MedTech...

MedTech Global Insights ·

2026/03/11

The European Union has just released a new, stringent regulation for AI and Machine Learning-enabled medical devices, creating an immediate and complex challenge for manufacturers worldwide. With an aggressive 18-month compliance deadline, this amendment demands unprecedented algorithmic transparency and robust bias validation, affecting both new and existing products on the market. This episode breaks down the critical details of this regulatory shift. We explore the new requirements for technical

en

02:08

Pure Global: U.S. FDA's Cyber War, Beyond the SBOM.

MedTech Global Insights ·

2026/03/10

The U.S. FDA has just released crucial new draft guidance on medical device cybersecurity, fundamentally changing the requirements for market approval. This isn't just a recommendation; it's a new reality for MedTech manufacturers, directly linked to new federal laws that give the agency power to reject submissions on cybersecurity grounds alone. This episode breaks down what the "Refuse to Accept" policy means for your product pipeline. We explore the mandatory inclusion of a Software Bill of

en

02:26

USA's LDT Crackdown: A Compliance Earthquake for Labs...

MedTech Global Insights ·

2026/03/09

The U.S. FDA has just finalized a rule that will shake the very foundations of the diagnostics industry. After decades of debate, Laboratory Developed Tests (LDTs) will now be regulated as medical devices. This move triggers a mandatory four-year transition that will impact thousands of hospital and clinical labs across the country, forcing them to comply with the same stringent regulations as commercial IVD manufacturers. This podcast episode unpacks the monumental shift from CLIA oversight to

en

02:01

Pure Global: Brazil's MDSAP Fast-Track for MedTech...

MedTech Global Insights ·

2026/03/08

This week on MedTech Global Insights, we explore a game-changing regulatory update from Brazil. ANVISA's new Resolution RDC 850/2024 allows medical device manufacturers to leverage their MDSAP certificate to extend the validity of their Brazil GMP certification, drastically simplifying market access. This move is a powerful signal of the growing trend toward global regulatory harmonization. We discuss how MedTech companies can turn this trend into a significant competitive advantage, using a single

en

211 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter